UBS Group’s Trevi Therapeutics TRVI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.94M | Buy |
354,225
+261,192
| +281% | +$1.43M | ﹤0.01% | 3856 |
|
|
2025
Q1 | $585K | Buy |
93,033
+47,518
| +104% | +$299K | ﹤0.01% | 4573 |
|
|
2024
Q4 | $188K | Buy |
45,515
+17,653
| +63% | +$72.7K | ﹤0.01% | 5288 |
|
|
2024
Q3 | $93.1K | Buy |
27,862
+9,853
| +55% | +$32.9K | ﹤0.01% | 5231 |
|
|
2024
Q2 | $53.7K | Sell |
18,009
-24,109
| -57% | -$71.8K | ﹤0.01% | 5495 |
|
|
2024
Q1 | $145K | Buy |
42,118
+10,741
| +34% | +$37.1K | ﹤0.01% | 4897 |
|
|
2023
Q4 | $42K | Buy |
31,377
+8,802
| +39% | +$11.8K | ﹤0.01% | 5445 |
|
|
2023
Q3 | $49.2K | Sell |
22,575
-1,480
| -6% | -$3.23K | ﹤0.01% | 5167 |
|
|
2023
Q2 | $57.5K | Buy |
24,055
+16,475
| +217% | +$39.4K | ﹤0.01% | 5335 |
|
|
2023
Q1 | $14K | Buy |
7,580
+4,489
| +145% | +$8.31K | ﹤0.01% | 6277 |
|
|
2022
Q4 | $5.97K | Sell |
3,091
-1,186
| -28% | -$2.29K | ﹤0.01% | 7905 |
|
|
2022
Q3 | $7K | Sell |
4,277
-494
| -10% | -$809 | ﹤0.01% | 7804 |
|
|
2022
Q2 | $13K | Buy |
4,771
+3,147
| +194% | +$8.58K | ﹤0.01% | 6514 |
|
|
2022
Q1 | $4K | Buy |
+1,624
| New | +$4K | ﹤0.01% | 8265 |
|
|
2021
Q4 | – | Sell |
-5,173
| Closed | -$7K | – | 9409 |
|
|
2021
Q3 | $7K | Buy |
5,173
+3,036
| +142% | +$4.11K | ﹤0.01% | 7183 |
|
|
2021
Q2 | $5K | Sell |
2,137
-241
| -10% | -$564 | ﹤0.01% | 7465 |
|
|
2021
Q1 | $6K | Buy |
+2,378
| New | +$6K | ﹤0.01% | 7214 |
|
|
2020
Q2 | – | Sell |
-541
| Closed | -$2K | – | 7319 |
|
|
2020
Q1 | $2K | Buy |
+541
| New | +$2K | ﹤0.01% | 6719 |
|
|
2019
Q4 | – | Sell |
-1,577
| Closed | -$7K | – | 7192 |
|
|
2019
Q3 | $7K | Sell |
1,577
-344
| -18% | -$1.53K | ﹤0.01% | 6384 |
|
|
2019
Q2 | $14K | Buy |
+1,921
| New | +$14K | ﹤0.01% | 5980 |
|